|
||||||
| Home |
| Find a Clinical Trial |
| Clinical Trial FAQs |
| About Informed Consent |
| Clinical Trials Glossary |
| Medical Research Areas |
| Clinical Trial Resources |
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
 |
|
|
|
|||
|
Novartis Clinical
Trials provides information about research studies recruiting
within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S. |
|
|
Find a Clinical Trial
Carcinoid Tumors
Carcinoid Tumors occur most often in the stomach or intestines. They are also sometimes found in the lungs. These tumors make hormones or other substances that usually only occur in very small amounts in the body. In some people, the excess hormones are associated with other symptoms, such as flushes (turning red and feeling warm) and diarrhea
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Carcinoid Syndrome Study - C2303
This research study will compare a Novartis investigative drug to octreotide LAR to determine which offers the best relief from diarrhea or flushing symptoms in people with carcinoid syndrome, who have not found relief from other treatment(s). An "investigational drug" is a drug that is being clinically tested and is not approved for sale or use in the United States by the Food and Drug Administration (FDA), for the indication in which it is being studied.
Trial phase: Phase 3 Participation Duration: Participants will be asked to visit the study site 10 times over about 10 months. Each visit should take about 2 hours. During the first month, participants will be required to make 3 visits, and then one visit per month thereafter. At the end of the study, participants will have an option to continue the study (in the extension portion) for another 24 months. Protocol Number: CSOM230C2303 |